跳至主要内容
临床试验/NL-OMON53199
NL-OMON53199已完成不适用

The feasibility of using a subtherapeutic dose of piracetam as a marker of adherence to therapy - Subtherapeutic dose of piracetam as a therapy adherence marker

ederlands Kanker Instituut0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • To be considered eligible to participate in this study, all of the following
  • requirements must be
  • 1. Age >= 18 years;
  • 2. Able and willing to give written informed consent;
  • 3. Able and willing to undergo urine sampling for analysis;
  • 4. Able and willing to digest multiple tablets at day one of each study week (6
  • 1.25 mg in week 1; 4 tablets of 1.25 mg in week 2; 2 tablets of 1.25 mg in week
  • 3 and 1 tablet of 1.25 mg in week 4)

排除标准

  • A potential subject who meets any of the following criteria will be excluded
  • from participation in this study:
  • 1. Current prescribed treatment with piracetam;
  • 2. Pregnant or breastfeeding;
  • 3. Criteria regarding the following contra-indications for piracetam:
  • - Cerebral haemorrhage;
  • - Huntington's chorea;
  • - Hypersensitivity to pyrrolide derivatives.

研究者

发起方
ederlands Kanker Instituut

相似试验